Follow
Mustafa özgüroğlu
Mustafa özgüroğlu
Verified email at istanbul.edu.tr - Homepage
Title
Cited by
Cited by
Year
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ...
New England Journal of Medicine 377 (20), 1919-1929, 2017
28912017
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ...
New England Journal of Medicine 379 (24), 2342-2350, 2018
18782018
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
K Fizazi, NP Tran, L Fein, N Matsubara, A Rodriguez-Antolin, ...
New England Journal of Medicine 377 (4), 352-360, 2017
15662017
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet 394 (10212), 1929-1939, 2019
8232019
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ...
The Lancet 392 (10142), 123-133, 2018
7992018
Apalutamide for metastatic, castration-sensitive prostate cancer
KN Chi, N Agarwal, A Bjartell, BH Chung, AJ Pereira de Santana Gomes, ...
New England Journal of Medicine 381 (1), 13-24, 2019
7342019
Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC
RS Herbst, G Giaccone, F de Marinis, N Reinmuth, A Vergnenegre, ...
New England Journal of Medicine 383 (14), 1328-1339, 2020
4912020
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
MD Galsky, JÁA Arija, A Bamias, ID Davis, M De Santis, E Kikuchi, ...
The Lancet 395 (10236), 1547-1557, 2020
3492020
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a …
K Fizazi, NP Tran, L Fein, N Matsubara, A Rodriguez-Antolin, ...
The Lancet Oncology 20 (5), 686-700, 2019
3382019
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
F Barlesi, J Vansteenkiste, D Spigel, H Ishii, M Garassino, F de Marinis, ...
The Lancet Oncology 19 (11), 1468-1479, 2018
3182018
Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC—update from PACIFIC
JE Gray, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ...
Journal of Thoracic Oncology 15 (2), 288-293, 2020
2982020
Survival with olaparib in metastatic castration-resistant prostate cancer
M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 383 (24), 2345-2357, 2020
2402020
Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial
C Faivre-Finn, D Vicente, T Kurata, D Planchard, L Paz-Ares, ...
Journal of Thoracic Oncology 16 (5), 860-867, 2021
1942021
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised …
A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, ...
The Lancet 397 (10274), 592-604, 2021
1852021
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN …
JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet Oncology 22 (1), 51-65, 2021
1492021
IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD …
D Spigel, F De Marinis, G Giaccone, N Reinmuth, A Vergnenegre, ...
Annals of Oncology 30, v915, 2019
1302019
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ...
The Lancet Oncology 22 (7), 931-945, 2021
1022021
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
K Kato, MA Shah, P Enzinger, J Bennouna, L Shen, A Adenis, JM Sun, ...
Future Oncology 15 (10), 1057-1066, 2019
962019
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
R Hui, M Özgüroğlu, A Villegas, D Daniel, D Vicente, S Murakami, T Yokoi, ...
The Lancet Oncology 20 (12), 1670-1680, 2019
952019
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L Paz-Ares, A Spira, D Raben, D Planchard, BC Cho, M Özgüroğlu, ...
Annals of Oncology 31 (6), 798-806, 2020
872020
The system can't perform the operation now. Try again later.
Articles 1–20